Group 1: Core Insights - In the first half of 2025, 47% of companies in the North Exchange's consumer services sector reported positive year-on-year growth in net profit attributable to shareholders [2][8] - The median revenue for these companies in H1 2025 was 236 million yuan, showing a slight decline of 0.36% year-on-year, while the median net profit attributable to shareholders was 15.23 million yuan, down 7.59% year-on-year [17][19] - In Q2 2025, the median revenue increased to 126 million yuan, reflecting a year-on-year growth of 1.88%, and the median net profit rose to 7.92 million yuan, marking a year-on-year increase of 4.5% [17][19] Group 2: Company Performance - Among the 38 companies, 14 reported both revenue and net profit growth in H1 2025, while 15 companies achieved sequential growth in both metrics in Q2 2025 [20][22] - Notable performers included Jinbo Biological, which achieved a revenue of 859 million yuan in H1 2025, a 42% increase year-on-year, and a net profit of 392 million yuan, up 26.65% [30] - Kangnong Seed Industry reported a significant increase in contract liabilities, up 410% year-on-year, indicating strong market acceptance of its products [26] Group 3: Market Trends - The median price-to-earnings (P/E) ratio for the consumer services sector increased from 51.7X to 51.8X, while the total market capitalization decreased from 126.47 billion yuan to 124.89 billion yuan [34][37] - The overall market performance for the consumer services sector showed a median decline of 1.99% in stock prices during the week of August 25 to August 29, 2025 [33][38] - The TTM median P/E ratio for the broader consumer sector rose by 8.98% to 72.3X, indicating a positive valuation trend [44][45] Group 4: Industry Insights - The TTM median P/E ratio for the food and beverage and agriculture sectors decreased from 47.9X to 45.8X, reflecting a shift in investor sentiment [46][47] - The professional technical services sector saw a decline in its TTM median P/E ratio from 32.2X to 31.2X, indicating potential challenges in valuation [50][51] - The consumer services sector's performance is influenced by various factors, including market competition and economic conditions, which are critical for future growth [2][8]

Core Insights - The "specialized and innovative" small giants are accelerating, with hidden champions in niche industries increasing their market share [1] - As of August 27, 2025, 192 out of 273 listed companies on the North Exchange have released their semi-annual reports, with a profitability rate of approximately 87.5% [1] - The majority of profitable companies are concentrated in the machinery equipment (24%), automotive (11%), electric power equipment (10%), and basic chemicals (10%) sectors [1] Revenue Performance - Nine companies on the North Exchange achieved revenue exceeding 1 billion yuan in the first half of 2025, with 150 companies surpassing 100 million yuan [3] - The top three companies by revenue are: - Innoway: 3.55 billion yuan - Tongli Co., Ltd.: 3.17 billion yuan - Yingtai Biotechnology: 2.97 billion yuan [4] Profitability - Three companies reported a net profit exceeding 100 million yuan, while 22 companies had a net profit over 50 million yuan [5] - Jinbo Biological, a leading company in the medical beauty and functional skincare sector, reported a net profit of 392 million yuan, a year-on-year increase of 26.65% [6][7] Growth Rates - Among the 22 companies that doubled their profits, Shibi Bai reported a staggering net profit growth of nearly 60 times, achieving a net profit of approximately 29.23 million yuan [9] - The company attributed its success to increased sales driven by government subsidies and improved internal management, leading to enhanced product quality and profit margins [9] Industry Trends - The machinery equipment sector has a high representation among the profitable companies, with Tongli Co., Ltd. being one of the notable firms with a market capitalization of approximately 10.31 billion yuan [9] - Tongli Co., Ltd. is actively advancing in the fields of new energy and autonomous driving, having delivered seven electric non-road dump trucks for a project in Mongolia [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong potential for stock price appreciation in the next six months [7]. Core Insights - The company achieved a revenue of 859 million yuan in H1 2025, representing a year-on-year increase of 42.43%. The net profit attributable to the parent company was 392 million yuan, up 26.65% [1][2]. - The growth in revenue is driven by strong performance in both medical devices and skincare products, with notable contributions from proprietary brands [2]. - The company has increased its marketing and R&D expenditures, leading to a rise in expense ratios, which has temporarily affected net profit margins [3]. - The introduction of new products, particularly in the recombinant collagen segment, is expected to enhance revenue growth in the future [4]. Financial Summary - For H1 2025, the company reported a gross margin of 90.68%, with a net profit margin of 45.66%. The gross margin remained stable, while the net profit margin declined due to increased expenses [3]. - Revenue projections for 2025-2027 are estimated at 2.177 billion yuan, 2.887 billion yuan, and 3.695 billion yuan, respectively, with net profits expected to reach 1.062 billion yuan, 1.433 billion yuan, and 1.865 billion yuan [4][5]. - The company’s earnings per share (EPS) is projected to grow from 9.23 yuan in 2025 to 16.21 yuan in 2027, reflecting strong growth potential [5]. Product and Market Position - The company is the only approved provider of recombinant collagen implants in the market, which is expected to enhance its market penetration [4]. - The skincare segment, particularly functional skincare products, has shown rapid growth, contributing significantly to overall revenue [2]. Expense and Profitability Analysis - The expense ratio for H1 2025 was 34.87%, with a notable increase in sales and R&D expenses. The sales expense ratio was 21.05%, reflecting increased marketing efforts [3]. - Despite the rise in expenses, the company maintains a high gross margin, indicating strong pricing power and operational efficiency [3].

Core Viewpoint - The company reported strong revenue growth in the first half of 2025, driven by its medical device and skincare product segments, indicating robust market demand and effective brand strategies [3][4]. Revenue Performance - The company's total revenue for the first half of 2025 reached 860 million yuan, a year-on-year increase of 42.4%, with net profit attributable to shareholders at 390 million yuan, up 26.7% [3]. - In Q1 and Q2 of 2025, revenues were 370 million yuan and 490 million yuan, reflecting year-on-year growth of 62.5% and 30.4%, respectively, while net profits were 170 million yuan and 220 million yuan, with increases of 66.3% and 7.4% [3]. Business Segment Analysis - Revenue from the medical device segment was 708 million yuan, growing by 33.41%, while functional skincare products saw a remarkable increase of 152.39% to 121 million yuan [4]. - The medical device revenue breakdown shows single-material devices at 645 million yuan (up 34.70%) and composite-material devices at 63 million yuan (up 21.52%) [4]. - Functional skincare products generated 19 million yuan from single-component products (up 59.76%) and 102 million yuan from composite-component products (up 182.85%) [4]. Regional Sales Performance - Revenue by region for the first half of 2025 was as follows: North China 365 million yuan (+25.66%), East China 287 million yuan (+72.95%), South China 79 million yuan (+17.88%), West China 85 million yuan (+79.68%), Central China 40 million yuan (+33.78%), and overseas 3 million yuan (+31.96%) [5]. - North and East China accounted for 75.91% of total revenue, highlighting their significance as primary markets [5]. Profitability Metrics - The company's gross margin decreased by 0.9 percentage points to 90.7% in the first half of 2025, influenced by a higher proportion of lower-margin skincare products and declining margins in the raw materials segment [6]. - The net profit margin for the first half of 2025 was 45.7%, down 5.7 percentage points year-on-year [6]. - In Q2 2025, the gross margin was 91.1%, with a net profit margin of 45.4%, reflecting a year-on-year decline of 0.3 and 9.8 percentage points, respectively [6]. Expense Analysis - The company's total expense ratio increased by 2.9 percentage points to 34.9% in the first half of 2025, driven by higher sales and marketing expenses due to new product launches and increased brand promotion efforts [7]. - Sales expenses accounted for 21.1% of total expenses, up 3.2 percentage points, while management and R&D expenses saw slight changes [7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4]. Core Insights - The company achieved a revenue of 859 million yuan in H1 2025, representing a year-on-year growth of 42.43%, while the net profit reached 392 million yuan, up 26.65% year-on-year [1]. - The gross margin for H1 2025 was 90.68%, a decrease of 0.9 percentage points, and the net profit margin was 45.5%, down 5.84 percentage points [1]. - The sales expense ratio increased to 21.05%, up 3.18 percentage points, attributed to higher personnel costs and promotional expenses [1]. - The medical device segment grew by 33.41% year-on-year, generating 708 million yuan in revenue, while the skincare segment saw a significant increase of 152.39%, reaching 121 million yuan [2]. - The company launched the HiveCOL collagen product and received medical device registration in Thailand, enhancing its international market presence [3]. Financial Performance - The company is projected to achieve earnings per share (EPS) of 12.11, 16.28, and 20.54 yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (PE) ratios of 26, 20, and 16 times [4]. - Revenue forecasts for 2025, 2026, and 2027 are 2.133 billion yuan, 2.790 billion yuan, and 3.503 billion yuan, respectively, with year-on-year growth rates of 47.84%, 30.79%, and 25.56% [6]. - The company’s return on equity (ROE) is expected to be 44.11%, 39.84%, and 35.70% for the years 2025, 2026, and 2027 [6].

Core Viewpoint - Jinbo Biological's strong financial performance in the first half of 2025 highlights its growth potential in the collagen protein market, driven by innovative product development and strategic partnerships [1][2][3]. Financial Performance - In the first half of 2025, Jinbo Biological achieved operating revenue of 859 million yuan, a year-on-year increase of 42.43%, and a net profit attributable to shareholders of 392 million yuan, up 26.65% [1]. - The company plans to distribute a cash dividend of 1.15 billion yuan, equivalent to 10.0 yuan per 10 shares [1]. Revenue Sources - Revenue growth was primarily driven by medical device products, which generated 708 million yuan, a 33.41% increase year-on-year, with a gross margin of 95.04% [2]. - Functional skincare products contributed 121 million yuan, reflecting a significant growth of 152.39% year-on-year, with a gross margin of 70.78% [2]. Research and Development - Jinbo Biological increased its R&D expenditure to 45.8 million yuan, accounting for 5.33% of operating revenue, marking an 85.43% increase compared to the previous year [2]. - The company collaborates with top research institutions, including Fudan University and Sichuan University, to enhance its R&D capabilities [2]. Product Innovation - The company launched the world's first "injection-type recombinant type III humanized collagen gel," approved by the National Medical Products Administration, showcasing its innovative capabilities [3]. - This product utilizes self-assembly and self-crosslinking technology, aimed at correcting mid-facial volume loss and contour defects [3]. Strategic Partnerships - Jinbo Biological has attracted a significant strategic investor, Yangshengtang Co., Ltd., planning to raise up to 2 billion yuan through a private placement [3]. - Following the issuance, Yangshengtang will hold over 5% of Jinbo Biological's shares, enhancing collaboration in R&D, production, and commercialization [3]. Market Outlook - The collagen protein market in China is expected to grow rapidly, with a projected compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [1][4]. - The increasing focus on skin health and medical aesthetics is driving the demand for recombinant humanized collagen in various applications [4].

Core Viewpoint - JINBO Biopharmaceutical (832982.BJ) reported strong growth in its 2025 semi-annual report, with significant increases in revenue and net profit, alongside a substantial rise in R&D expenses, indicating a focus on innovation and market expansion [1][2][8]. Financial Performance - As of June 30, 2025, JINBO Biopharmaceutical achieved an operating revenue of approximately 859 million yuan, representing a year-on-year growth of 42.43% [2]. - The company recorded a net profit attributable to shareholders of approximately 392 million yuan, reflecting a year-on-year increase of 26.65% [2]. - The gross profit margin remained above 90%, specifically at 90.68%, earning the company the nickname "Little Moutai" on the Beijing Stock Exchange [2]. Revenue Growth Drivers - The increase in operating revenue was primarily driven by growth in medical devices and functional skincare products [3]. - Medical device revenue growth was mainly attributed to the sales of implant products based on recombinant human collagen [4]. - Functional skincare products saw a remarkable revenue increase of approximately 121 million yuan, up 152.39% year-on-year, indicating significant scale effects [5]. R&D Investment - JINBO Biopharmaceutical's R&D expenses reached 45.7962 million yuan, a substantial increase of 85.43% compared to the previous year, accounting for 5.33% of operating revenue [8]. - The rise in R&D spending was largely due to increased collaboration with institutions like Peking University and higher costs associated with clinical trials [9]. Market Performance - Since the beginning of 2025, JINBO Biopharmaceutical's stock has experienced a continuous upward trend, with a year-to-date increase of 101.92%, reaching a peak of 452.29 yuan per share on May 22 [12]. - The current price-to-earnings ratio (TTM) stands at 46.06, with a total market capitalization of approximately 36.824 billion yuan [12]. Institutional Interest - The semi-annual report revealed that several institutions and public funds have increased their holdings in JINBO Biopharmaceutical during the first half of the year [14]. - Notably, CITIC Securities became the eighth largest shareholder after acquiring 782,390 shares, while two funds from Ping An Bank and China Merchants Bank also increased their stakes [15][16].

Core Viewpoint - The demand slowdown is impacting Jinbo Biological, the first stock of recombinant collagen on the Beijing Stock Exchange, as evidenced by its recent financial performance and stock price decline [1][3]. Financial Performance - In the first half of 2025, Jinbo Biological reported revenues of 859 million yuan and a net profit attributable to shareholders of 392 million yuan, representing year-on-year growth of 42.43% and 26.65% respectively [1]. - However, the revenue growth rate has significantly slowed, with a 48 percentage point decrease compared to the same period in 2024, marking the first time since its listing in July 2023 that revenue growth fell below 40% [1]. Product Performance - The slowdown in performance is primarily attributed to the decline in sales of its medical device product "Wei Yimei," which is based solely on recombinant collagen [3]. - In the first half of 2025, Wei Yimei generated 645 million yuan in revenue, with a year-on-year growth of 34.7%, a drop of over 70 percentage points compared to the same period in 2024 [3]. Market Strategy - In July 2023, Jinbo Biological partnered with Meituan to promote Wei Yimei through a "100 billion subsidy" initiative, which has led to a significant drop in terminal prices [5]. - The price for new customers in Beijing for Wei Yimei has decreased by over 40% compared to the previous year's subsidized price, with subsequent prices dropping by more than 70% from the original guidance [5]. Growth in Other Segments - Despite the slowdown in the medical beauty segment, Jinbo Biological's cosmetics revenue is experiencing high growth, with functional skincare brands like "Zhongyuan" and "ProtYouth" generating 121 million yuan in the first half of 2025, a year-on-year increase of 152% [5]. Strategic Partnerships - Jinbo Biological has engaged with Zhong Shanshan's Yangshengtang to establish a broader sales promotion system, leveraging Yangshengtang's extensive distribution network through its subsidiary Nongfu Spring [6][7]. - This partnership is expected to enhance market penetration for Jinbo Biological's skincare brands, although it may challenge the valuation scarcity of Jinbo Biological as a supplier in the medical beauty sector [7]. Valuation Comparison - Currently, Jinbo Biological's price-to-earnings (PE) ratio is around 40 times, while leading A-share cosmetics company Proya has a PE ratio of approximately 20 times [8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a revenue of 860 million yuan in H1 2025, representing a year-on-year increase of 42.4%, with a net profit of 390 million yuan, up 26.7% year-on-year [7] - The sales of medical device products remained stable, while functional skincare products saw significant growth, with revenue from medical devices, functional skincare, and raw materials reaching 710 million, 120 million, and 30 million yuan respectively in H1 2025, reflecting year-on-year growth of 33.4%, 152.4%, and 12.4% [7] - The company launched the world's first injectable gel product in April 2025, which is expected to drive domestic growth [7] - Strategic partnerships are being strengthened to accelerate international expansion, with plans to recruit partners in Thailand for medical device distribution [7] - The long-term growth outlook remains positive, with adjusted net profit forecasts for 2025-2027 being 1.04 billion, 1.46 billion, and 1.86 billion yuan respectively [7] Financial Summary - Total revenue is projected to reach 2.10 billion yuan in 2025, with a year-on-year growth rate of 45.81% [1] - The company's net profit is expected to grow to 1.04 billion yuan in 2025, reflecting a growth rate of 42.09% [1] - The latest diluted EPS is forecasted to be 9.04 yuan per share in 2025, with a P/E ratio of 35.39 [1]

Core Viewpoint - Jinbo Biological has reported strong financial performance for the first half of the year, indicating significant growth in revenue and net profit, alongside a planned cash dividend distribution to shareholders [1][2][3]. Financial Performance - The company achieved a revenue of 859 million yuan, representing a year-on-year increase of 42.43% [2]. - The net profit attributable to shareholders was 392 million yuan, reflecting a year-on-year growth of 26.65% [2]. - The gross profit margin decreased slightly to 90.68% from 91.58% in the previous year [2]. - Basic earnings per share were reported at 3.41 yuan [2]. Business Growth Drivers - The revenue growth was primarily driven by increased sales in medical devices and functional skincare products [2]. - The medical device segment saw growth mainly from the sales of implant products based on type A recombinant human collagen [2]. - The functional skincare segment benefited from the sales of proprietary brands such as "重源" and "ProtYouth®" [2]. Company Background - Jinbo Biological is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province [3]. - The company was listed on the Beijing Stock Exchange on July 20, 2023, with an initial market capitalization of 8.757 billion yuan, which has since increased to nearly 37 billion yuan [3]. Future Prospects - The company plans to utilize funds from a recent share transfer to enhance its research and development capabilities, particularly in the area of humanized collagen products [6][7]. - The total investment for the new FAST database and product development platform project is approximately 1.26 billion yuan, with a three-year implementation period [6].